Literature DB >> 23467925

Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria.

Yun-Hsuan Lee1, Cheng-Yuan Hsia, Chia-Yang Hsu, Yi-Hsiang Huang, Han-Chieh Lin, Teh-Ia Huo.   

Abstract

BACKGROUND: The Milan criteria are used to define small hepatocellular carcinoma (HCC) and to select patients for curative treatments. Total tumor volume (TTV) is an alternative parameter for tumor burden. We aimed to evaluate whether TTV is a feasible prognostic marker in HCC patients with upper boundary TTV of 65.5 cm(3), which is equivalent to a single 5 cm tumor nodule defined by the Milan criteria.
METHODS: A total of 774 HCC patients with TTV <65.5 cm(3) receiving surgical resection, liver transplantation, or radiofrequency ablation (RFA) as the primary treatment were retrospectively analyzed.
RESULTS: Of these patients, 50 (6.5 %) did not fulfill the Milan criteria. Patients beyond the Milan criteria more often had larger tumor size and TTV, as well as more tumor nodules (p values all <0.01). There was no significant survival difference between patients within and beyond the Milan criteria (p = 0.205). Patients with TTV >15 cm(3) had a significantly poorer survival than patients with TTV <15 cm(3) (p = 0.007). There was no survival difference between patients receiving surgical treatments versus RFA (p = 0.932). In the Cox proportional hazards model, TTV >15 cm(3) [risk ratio (RR): 1.474, p = 0.005], serum bilirubin ≥ 1.5 mg/dL (RR: 1.663, p = 0.003), serum sodium <135 mmol/L (RR: 2.016, p = 0.01), and α-fetoprotein (AFP) ≥ 100 ng/mL (RR: 1.37, p = 0.033) were independent predictors of poor prognosis.
CONCLUSIONS: Total tumor volume, is an independent and better prognostic marker than the Milan criteria to indicate tumor burden in HCC patients who had tumor volume defined by the Milan criteria and underwent curative therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23467925     DOI: 10.1007/s00268-013-1978-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  27 in total

Review 1.  Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review.

Authors:  Yun Ku Cho; Hyunchul Rhim; Sangik Noh
Journal:  J Gastroenterol Hepatol       Date:  2011-09       Impact factor: 4.029

2.  Prognostic factors and outcome of 438 Chinese patients with hepatocellular carcinoma underwent partial hepatectomy in a single center.

Authors:  Jie Wang; Lei-Bo Xu; Chao Liu; Hao-Wei Pang; Ya-Jin Chen; Qing-Jia Ou
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

Review 3.  Transplantation for hepatocellular carcinoma: The Milan criteria and beyond.

Authors:  Richard B Freeman
Journal:  Liver Transpl       Date:  2006-11       Impact factor: 5.799

4.  Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening.

Authors:  Po-Lin Tseng; Jing-Houng Wang; Hung-Da Tung; Chao-Hung Hung; Kwong-Ming Kee; Chien-Hung Chen; Kuo-Chin Chang; Chuan-Mo Lee; Chi-Sin Changchien; Pao-Fei Chen; Lin-San Tsai; Sheng-Nan Lu
Journal:  J Gastroenterol Hepatol       Date:  2010-08       Impact factor: 4.029

Review 5.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Liver transplantation for hepatocellular carcinoma: defining the impact of using extended criteria liver allografts.

Authors:  Marcelo E Facciuto; Manoj K Singh; Umadevi Katta; Susana Samaniego; Jyoti Sharma; Manuel Rodriguez-Davalos; Patricia Sheiner; Leona Kim-Schluger; David C Wolf
Journal:  Transplantation       Date:  2011-08-27       Impact factor: 4.939

7.  Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis.

Authors:  Yuan-Hung Kuo; Sheng-Nan Lu; Chao-Long Chen; Yu-Fan Cheng; Chih-Yun Lin; Chao-Hung Hung; Chien-Hung Chen; Chi-Sin Changchien; Hsuan-Chih Hsu; Tsung-Hui Hu; Chuan-Mo Lee; Jing-Houng Wang
Journal:  Eur J Cancer       Date:  2010-01-08       Impact factor: 9.162

8.  Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.

Authors:  Christian Toso; Sonal Asthana; David L Bigam; A M James Shapiro; Norman M Kneteman
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

Review 10.  Liver transplantation for hepatocellular carcinoma.

Authors:  Vincenzo Mazzaferro; Yun Shin Chun; Ronnie T P Poon; Myron E Schwartz; Francis Y Yao; J Wallis Marsh; Sherrie Bhoori; Sung-Gyu Lee
Journal:  Ann Surg Oncol       Date:  2008-01-31       Impact factor: 5.344

View more
  12 in total

1.  Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.

Authors:  Michał Grąt; Oskar Kornasiewicz; Zbigniew Lewandowski; Wacław Hołówko; Karolina Grąt; Konrad Kobryń; Waldemar Patkowski; Krzysztof Zieniewicz; Marek Krawczyk
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

Review 2.  When to consider liver transplantation in hepatocellular carcinoma patients?

Authors:  Ka Wing Ma; Tan To Cheung
Journal:  Hepat Oncol       Date:  2017-07-06

3.  Resources Required for Semi-Automatic Volumetric Measurements in Metastatic Chordoma: Is Potentially Improved Tumor Burden Assessment Worth the Time Burden?

Authors:  Kathleen E Fenerty; Nicholas J Patronas; Christopher R Heery; James L Gulley; Les R Folio
Journal:  J Digit Imaging       Date:  2016-06       Impact factor: 4.056

4.  Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma.

Authors:  Mu-Xing Li; Hong Zhao; Xin-Yu Bi; Zhi-Yu Li; Zhen Huang; Yue Han; Jian-Guo Zhou; Jian-Jun Zhao; Ye-Fan Zhang; Wen-Qiang Wei; Dong-Bin Zhao; Jian-Qiang Cai
Journal:  Tumour Biol       Date:  2016-01-15

5.  Alpha-fetoprotein level to total tumor volume as a predictor of hepatocellular carcinoma recurrence after resection. A retrospective cohort study.

Authors:  Hazem M Zakaria; Anwar Mohamed; Hazem Omar; Nahla K Gaballa
Journal:  Ann Med Surg (Lond)       Date:  2020-05-04

6.  Total tumor volume as a prognostic value for survival following liver resection in patients with hepatocellular carcinoma. Retrospective cohort study.

Authors:  Hazem M Zakaria; Mahmoud Macshut; Nahla K Gaballa; Ahmed E Sherif; Mohammed E Abdel-Samea; Mohamed Abdel-Samiee; Ibrahim Marwan; Taha Yassein
Journal:  Ann Med Surg (Lond)       Date:  2020-04-07

7.  Total tumour volume as a prognostic factor in patients with resectable colorectal cancer liver metastases.

Authors:  K Tai; S Komatsu; K Sofue; M Kido; M Tanaka; K Kuramitsu; M Awazu; H Gon; D Tsugawa; H Yanagimoto; H Toyama; S Murakami; T Murakami; T Fukumoto
Journal:  BJS Open       Date:  2020-04-11

8.  The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.

Authors:  Tao Jiang; Xiao-Shi Zhang; Fei Pan; Shao-Cheng Lyu; Jing Wang; Meng-Xiu Huang; Qiang He; Ren Lang
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

9.  The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.

Authors:  Fei-Xiang Wu; Jie Chen; Tao Bai; Shao-Liang Zhu; Tian-Bo Yang; Lu-Nan Qi; Ling Zou; Zi-Hui Li; Jia-Zhou Ye; Le-Qun Li
Journal:  BMC Cancer       Date:  2017-09-12       Impact factor: 4.430

Review 10.  Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong.

Authors:  Ka Wing Ma; Kenneth Siu Ho Chok; James Yan Yue Fung; Chung Mau Lo
Journal:  J Clin Transl Hepatol       Date:  2018-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.